“Telmisartan Attenuates Experimental Liver Fibrosis Through Suppression Of Hepatic Stellate Cell Activation And Tgf-Β Smad Signaling”. The Review of Diabetic Studies (June 12, 2026): 62–76. Accessed June 12, 2026. https://www.diabeticstudies.org/index.php/RDS/article/view/2052.